Evidence map›Paper›PMID 42311373›Full record

ArticleEuropean heart journal. Case reports2026

Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report.

Simon Lucas, Benjamin Hennart, Pascal de Groote, Nicolas Lamblin, Helene Ridon, Celine Dupre, Arnaud Lionet, Gilles Lemesle

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simon LucasCardiology Department, Heart and Lung Institute, University Hospital of Lille, CHU Lille, Bd du Pr Jules Lecle rcq, 59000 Lille, France.
Benjamin HennartToxicology and Genopathy Department, University Hospital of Lille, CHU Lille, Avenue Oscar Lambret, 59000 Lille, France.
Pascal de GrooteCardiology Department, Heart and Lung Institute, University Hospital of Lille, CHU Lille, Bd du Pr Jules Lecle rcq, 59000 Lille, France.
Nicolas LamblinCardiology Department, Heart and Lung Institute, University Hospital of Lille, CHU Lille, Bd du Pr Jules Lecle rcq, 59000 Lille, France.ORCID https://orcid.org/0000-0003-3754-1241
Helene RidonDepartment of Cardiovascular Explorations, Heart and Lung Institute, University Hospital of Lille, Bd du Pr Jules Leclercq, 59000 Lille, France.
Celine DupreDepartment of Anesthesia and Intensive Care, Heart and Lung Institute, University Hospital of Lille, Bd du Pr Jules Leclercq, 59000 Lille, France.
Arnaud LionetUniversité de Lille, rue Paul Duez, 59000 Lille, France.
Gilles LemesleCardiology Department, Heart and Lung Institute, University Hospital of Lille, CHU Lille, Bd du Pr Jules Lecle rcq, 59000 Lille, France.ORCID https://orcid.org/0000-0002-2917-9273

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mavacamten has been shown to be efficient in the treatment of obstructive hypertrophic cardiomyopathy (HOCM). However, its use may be associated with toxicity and subsequent adverse events. Case summary: We report the case of a 39-year-old woman with a history of sleeve gastrectomy and HOCM. She was initiated on mavacamten 5 mg once daily Discussion: The present case highlights that drug interactions in patients with HOCM receiving mavacamten are critical and may lead to a high level of toxicity and severe heart failure events, including cardiogenic shocks. Patient and caregiver information about these potential interactions is highly important. This case also emphasizes that the dosage of mavacamten is now available (and should be used in specific situations) and that mavacamten toxicity can rapidly be overcome by early rifampicin administration, a strong hepatic enzyme inducer.

Indexed as

Cardiogenic shockCase reportCytochrome CYP2C19Drug interactionsHypertrophic cardiomyopathyMavacamtenRifampicin

Identifiers

PMID42311373
PMCPMC13270335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.